Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

Between December 2005 and October 2009, FDA approved six targeted therapies shown to significantly extend survival for advanced renal cell carcinoma (RCC) patients in clinical trials. This study aimed to examine changes in survival between the pretargeted and targeted therapy periods in advanced RCC...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2015
Subjects:
Clinical Cancer Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4735783/
https://ncbi.nlm.nih.gov/pubmed/26645975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.574
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items